MedTrace Logo

BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors

NCT00526149 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2013-10-07

No results posted yet for this study

Summary

RATIONALE: BI 2536 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase II trial is studying the side effects and how well BI 2536 works in treating patients with recurrent or metastatic solid tumors.

Conditions

Interventions

DRUG

BI 2536

OTHER

high performance liquid chromatography

OTHER

mass spectrometry

OTHER

pharmacological study

Sponsors & Collaborators

  • European Organisation for Research and Treatment of Cancer - EORTC

    lead NETWORK

Principal Investigators

  • Patrick Schoffski, MD, MPH · University Hospital, Gasthuisberg

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2008-09-30

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00526149 on ClinicalTrials.gov